|
|
| Disclaimer |
 |
 |
|
This website is not intended to be used as a substitute for obtaining qualified medical advice or seeking treatment from a physician. Visitors to this site should not rely on the information contained for their particular condition or as a substitute for receiving qualified medical advice. If you are having an acute health problem, go to an emergency room or call your doctor or your local emergency health service.
The mSEPT9 blood test for colorectal cancer is a product in development by Epigenomics and its partners and it is among the objectives of the PRESEPT Study to provide scientific evidence that supports the regulatory approval and guideline inclusion of future in vitro diagnostic products that are based on the mSEPT9 biomarker. Currently no performance of any SEPT9 based in vitro diagnostic product has been evaluated by the FDA or other regulatory authorities and SEPT9 testing is not recommended by any colorectal cancer screening guideline in the U.S. or elsewehere.
We strongly recommend that individuals that are eligible for colorectal cancer screening follow the guideline recommendations in their respective countries and make best use the screening methods currently available.
Colorectal cancer screening can save your life! Don’t wait!
The information contained in this website does not constitute nor imply an offer to sell or transfer any product, and no product based on this technology is currently available for sale in the United States. The analytical and clinical performance characteristics of any product based on this technology which may be sold at some future time in the U.S. have not been established.
|
|
|
|
top of the page
|
